Biotech Values

[oc631]

I am of the understanding that MNTA will clearly suffer irreparable harm

Let me add my two cents, which is worth about one cent, considering the quality of my MNTA posts. MNTA chose to sign a unique front end loaded, profit share contract with Sandoz. They could have signed a deal with a higher royalty rate (without the third party entry clause) yet they chose the higher risk deal and now they are in a bind because of Amp's approval. Isn't the "irreparable harm" partly their fault since they assumed more contract risk than needed? Will the judge take this into consideration after ruling on the case?